BiotechTube
Oxeia Biopharmaceuticals

Oxeia Biopharmaceuticals

San Diego, United States· Est.
oxeiabiopharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12.5M

Overview

Oxeia Biopharmaceuticals is a private, pre-revenue biotech targeting a significant unmet need: an FDA-approved therapy for persistent concussion symptoms (post-concussion syndrome). The company's lead small molecule drug, OXE103, showed an 85% responder rate in a Phase 2a pilot study, positioning it for a planned Phase 2b trial in 2026. Oxeia is currently raising capital via an equity crowdfunding campaign on StartEngine to fund this next development stage, operating in a large market with no approved pharmacological treatments.

NeurologyTraumatic Brain Injury

Technology Platform

Novel small molecule therapeutic targeting neuro-metabolic dysfunction underlying concussion.

Funding History

2
Total raised:$12.5M
Series A$10M
Seed$2.5M

Opportunities

The company operates in a massive, completely untreated market with millions of annual concussion cases and zero FDA-approved therapies.
Success would mean first-mover advantage in a space with significant unmet medical need and high awareness.
Positive Phase 2b data could attract partnership or acquisition interest from larger neurology-focused pharma companies.

Risk Factors

High clinical risk that Phase 2b/3 trials fail to confirm promising early data.
Regulatory risk in pioneering an approval pathway for a new indication.
Financial risk due to reliance on crowdfunding and future dilutive financing.
Competitive risk from other entities developing concussion therapies.

Competitive Landscape

There are currently no FDA-approved pharmacological treatments for concussion, making the competitive landscape for a specific approved drug essentially empty. However, competition exists from off-label use of medications for symptoms (e.g., headache, depression) and from other companies in earlier preclinical or clinical stages also targeting TBI. Oxeia's advanced Phase 2a data provides a potential timing advantage.

More companies in United States →